Ultragenyx Phase 3 Angelman trial misses goals
Ultragenyx’s Phase 3 Aspire trial of apazunersen in Angelman syndrome failed key efficacy endpoints, prompting a review of the program and planned significant cost reductions.
Rhea-AI Filing Summary
Ultragenyx Pharmaceutical Inc. (RARE) reported that its Phase 3 Aspire study of apazunersen (GTX-102) in Angelman syndrome did not meet the primary endpoint of change from Baseline in Bayley-4 cognitive raw score or the key secondary endpoint of net response in the Multidomain Responder Index. The safety profile in Aspire was consistent with the earlier Phase 1/2 study, and randomized groups were comparable at baseline. Ultragenyx plans to evaluate the future of the apazunersen program in light of these results and to assess its planned operations to define and implement significant expense reductions while continuing to support its growing commercial business.
Positive
- None.
Negative
- Phase 3 Aspire study for apazunersen in Angelman syndrome failed its primary and key secondary efficacy endpoints, removing a potential late-stage pipeline value driver.
- Ultragenyx plans to implement significant expense reductions, indicating potential restructuring and cost-cutting in response to the unsuccessful trial outcome.
Insights
Analyzing...
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Announcement date: September 2, 2026
Trial phase: Phase 3
Key efficacy endpoints not met: 2 endpoints
3 metrics
Announcement date
September 2, 2026
Date Ultragenyx reported Phase 3 Aspire trial results for apazunersen
Trial phase
Phase 3
Stage of Aspire study for apazunersen in Angelman syndrome
Key efficacy endpoints not met
2 endpoints
Primary Bayley-4 cognitive raw score and key secondary MDRI net response
Key Terms
Phase 3 Aspire study, Angelman syndrome, Bayley-4 cognitive raw score, Multidomain Responder Index, +1 more
5 terms
Phase 3 Aspire study medical
"announced results from the Phase 3 Aspire study for apazunersen"
Angelman syndrome medical
"apazunersen (GTX-102) in Angelman syndrome"
A rare genetic disorder that causes severe developmental delays, problems with movement and balance, limited speech, and frequent seizures; it results from a missing or malfunctioning gene that acts like a broken instruction in the body’s manual for brain development. Investors watch it because treatments are a focus of drug development—successful therapies or clinical trial results can change the commercial outlook for biotech firms working on targeted genetic or neurological medicines.
Bayley-4 cognitive raw score medical
"primary endpoint of change from Baseline in Bayley-4 cognitive raw score"
Multidomain Responder Index medical
"key secondary endpoint of net response in Multidomain Responder Index"
significant expense reductions financial
"assess its planned operations to define and implement significant expense reductions"
FAQ
What did Ultragenyx (RARE) announce about the Phase 3 Aspire study for apazunersen?
Ultragenyx announced that the Phase 3 Aspire study of apazunersen (GTX-102) in Angelman syndrome did not achieve its primary Bayley-4 cognitive raw score endpoint or the key secondary MDRI net response endpoint. The company will evaluate the program based on this outcome.
Which endpoints were missed in Ultragenyx’s Aspire Phase 3 trial reported in this 8-K?
The trial missed the primary endpoint of change from Baseline in Bayley-4 cognitive raw score and the key secondary endpoint of net response in the Multidomain Responder Index, with no supportive differences seen between treated and control groups.
How was the safety profile of apazunersen in the Phase 3 Aspire study according to Ultragenyx (RARE)?
Ultragenyx reported that the safety profile of apazunersen in the Phase 3 Aspire study was consistent with the Phase 1/2 study, indicating no new safety issues were observed in the larger, randomized setting.
What operational changes does Ultragenyx plan following the Aspire Phase 3 results?
Ultragenyx stated it will assess its planned operations to define and implement significant expense reductions, while continuing to support its growing commercial business after the unsuccessful Aspire Phase 3 trial outcome.
What are the implications for Ultragenyx’s apazunersen program after the Aspire trial results?
Ultragenyx said it will evaluate the apazunersen program in light of the Phase 3 Aspire trial failing key endpoints and then make a decision on its disposition, which could include changes to or discontinuation of the program.
When did Ultragenyx announce the Aspire Phase 3 trial results for apazunersen?
Ultragenyx announced the Aspire Phase 3 trial results for apazunersen on September 2, 2026, as disclosed in the current report signed by Executive Vice President and Chief Financial Officer, Corporate Strategy, Howard Horn.
AI-generated analysis. How Rhea-AI works. Not financial advice.
